Clinical trial

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

NCT05773092

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2023-08-01

PhasePHASE2

Study timeline

Study start (actual)2023-08-01Date precision: day

Registry last updated2026-06-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

NSCLCunresolved

Interventions

Oral S-1 + Oral OsimertinibDRUG

Sponsors & collaborators

National Cancer Centre, Singaporelead sponsor

Taiho Pharmaceutical Co., Ltd.collaborator

Mapped research locations

SingaporeSingapore1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05773092 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.